Ben Hirschler – Page 16

Exclusive: GSK set for Human Genome takeover – sources

December 24, 2018 at 9:28 a.m.

NEW YORK/LONDON (Reuters) - GlaxoSmithKline is expected to announce an agreement to acquire Human Genome Sciences for about $2.8 billion as soon as Monday, ending three months of its hostile...

GSK in weekend talks to buy Human Genome: sources

August 23, 2021 at 10:41 a.m.

LONDON/NEW YORK (Reuters) - GlaxoSmithKline is holding talks this weekend with Human Genome Sciences to agree a deal to acquire it for some $2.6 billion, after pursuing the U.S. biotech...

GSK in weekend talks to buy Human Genome: sources

December 24, 2018 at 9:31 a.m.

LONDON/NEW YORK (Reuters) - GlaxoSmithKline is holding talks this weekend with Human Genome Sciences to agree a deal to acquire it for some $2.6 billion, after pursuing the U.S. biotech...

Analysis: Bird flu vaccine now? More than a shot in the dark

August 23, 2021 at 10:28 a.m.

LONDON (Reuters) - Culls of hundreds of thousands of chickens, turkeys and ducks to stem bird flu outbreaks rarely make international headlines these days, but they are a worryingly common...

Analysis: Bird flu vaccine now? More than a shot in the dark

May 13, 2019 at 7:15 p.m.

LONDON (Reuters) - Culls of hundreds of thousands of chickens, turkeys and ducks to stem bird flu outbreaks rarely make international headlines these days, but they are a worryingly common...

Drug pipelines improving after years in doldrums

August 23, 2021 at 9:50 a.m.

LONDON (Reuters) - Drug industry productivity is finally improving after years of research disappointment, as drugmakers shift their focus from mass markets to making medicines for rarer, under-treated diseases. Data...

Drug pipelines improving after years in doldrums

May 13, 2019 at 7:02 p.m.

LONDON (Reuters) - Drug industry productivity is finally improving after years of research disappointment, as drugmakers shift their focus from mass markets to making medicines for rarer, under-treated diseases. Data...

UK cost agency rejects Roche’s new melanoma pill

August 23, 2021 at 9:18 a.m.

LONDON (Reuters) - Swiss group Roche's new melanoma drug Zelboraf has been rejected in a preliminary ruling by Britain's healthcare cost agency, triggering a fresh clash between the world's biggest...

UK cost agency rejects Roche’s new melanoma pill

May 13, 2019 at 6:50 p.m.

LONDON (Reuters) - Swiss group Roche's new melanoma drug Zelboraf has been rejected in a preliminary ruling by Britain's healthcare cost agency, triggering a fresh clash between the world's biggest...

Scientists unlock gene secrets of opium poppy drug

August 23, 2021 at 8:16 a.m.

LONDON (Reuters) - Scientists have unravelled exactly how opium poppies produce a non-addictive compound that can both suppress coughs and kill tumor cells, paving the way for improved production of...

All Stories